Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market.

JAMA Netw Open · 2025 · PMC12606378 · PMID 41217752

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Except for filgrastim, the ASP per dose for all biologics showed a decreasing trend in the subsequent years.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.